Recent advances in targeting mTOR signaling pathway using small molecule inhibitors (Q38955246)

7 September 2017

1 reference

title

Recent advances in targeting mTOR signaling pathway using small molecule inhibitors (English)

1 reference

7 September 2017

Mohammad Hojjat-Farsangi

series ordinal

2

1 reference

7 September 2017

Azam Roohi

1

1 reference

7 September 2017

15 September 2016

1 reference

Journal of Drug Targeting

7 September 2017

1 reference

7 September 2017

25

1 reference

7 September 2017

3

1 reference

7 September 2017

189-201

1 reference

A year in structural signaling: mTOR--the PIKK of the bunch?

7 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The mTOR signalling pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Mechanisms of tumor cell resistance to the current targeted-therapy agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

An evolving role for DEPTOR in tumor development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mLST8 Promotes mTOR-Mediated Tumor Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Tti1 and Tel2 are critical factors in mammalian target of rapamycin complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Rheb signaling and tumorigenesis: mTORC1 and new horizons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Rheb Inhibits Protein Synthesis by Activating the PERK-eIF2α Signaling Cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Regulation of mTORC1 by PI3K signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

LKB1 Tumor Suppressor: Therapeutic Opportunities Knock when LKB1 Is Inactivated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Hypoxia and mitochondrial oxidative metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Role of the Akt pathway in mRNA translation of interferon-stimulated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

PI3K/Akt mediates expression of TNF-alpha mRNA and activation of NF-kappaB in calyculin A-treated primary osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Growth suppressive cytokines and the AKT/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Regulation of immune responses by mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Novel G proteins, Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Sestrin2 is a leucine sensor for the mTORC1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Regulation of translation initiation by FRAP/mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Coordinate regulation of translation by the PI 3-kinase and mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Novel and emerging targeted-based cancer therapy agents and methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Protein turnover via autophagy: implications for metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

ULK1 inhibits the kinase activity of mTORC1 and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Feedback regulation of mTORC1 by Grb10 in metabolism and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Connecting mTORC1 signaling to SREBP-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Activation of mTORC2 by association with the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Leucine facilitates the insulin-stimulated glucose uptake and insulin signaling in skeletal muscle cells: involving mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

TORC2 Structure and Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Role of mTOR signaling in tumor cell motility, invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Retracted: Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Autophagy inhibition sensitizes KU-0063794-mediated anti-HepG2 hepatocellular carcinoma cell activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Pushing the envelope in the mTOR pathway: the second generation of inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Rapamycins: mechanism of action and cellular resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

ATP-competitive inhibitors of mTOR: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Toward rapamycin analog (rapalog)-based precision cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Cellular and molecular effects of the mTOR inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mTOR pathway and mTOR inhibitors as agents for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Targeting mTOR pathways in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Combination of mTOR Inhibitors Augments Potency while Activating PI3K Signaling in Pituitary Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Rapamycin induces mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) expression through activation of protein kinase B and mitogen-activated protein kinase kinase pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Ibrutinib-A double-edge sword in cancer and autoimmune disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

PI3K and mTOR inhibitors: a new generation of targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F1061186X.2016.1236112

10.1080/1061186X.2016.1236112

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27632356